|
|
|||
| |||||||||||||||||||||||||||||||
Litigation concerning mass toxic substances (i.e., substances affecting many thousands of people) has become a permanent feature of the medical landscape, in no small measure as a result of the rise and fall of Bendectin. Michael Green, a professor of law at the University of Iowa, tells the scientific, clinical, and legal story of Bendectin by chronicling the case of Mekdeci v. Merrell National Laboratories, from David Mekdeci's birth in 1975 with anomalies his mother thought were due to Bendectin, to the 1980 trial in which the Mekdecis were awarded only $20,000 in an equivocal decision by the jury, to
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved. |